Stemtech Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a STEK research report →
Price Chart
About the company
Stemtech Corporation is a pioneering company specializing in stem cell nutrition. It formulates scientifically-backed products designed to optimize the body's intrinsic stem cell physiology. With a market presence spanning the Americas, Latin America, and Asia, its offerings are engineered to bolster the natural functions of the body's stem cells.
- CEO
- Charles S. Arnold
- IPO
- 2021
- Employees
- 1
- HQ
- Naples, FL, US
Get TickerSpark's AI analysis on STEK
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $216.93K
- P/E
- -0.01
- PEG
- -0.00
- P/S
- 0.09
- P/B
- -0.03
- EV/EBITDA
- -1.09
- Div Yield
- 0.00%
- Gross Margin
- 77.27%
- Op Margin
- -100.84%
- Net Margin
- -159.69%
- ROE
- 55.68%
- ROIC
- 26.25%
Latest fiscal year · YoY change
- Revenue
- $2.88M-43.1%
- Gross Profit
- $2.31M-38.0%
- Op Income
- $-2,709,047
- Net Income
- $-4,046,705-7.4%
- EPS
- $-0.02+25.2%
- OCF Growth
- +19.6%
- FCF Growth
- +19.6%
- 52W High
- $0.01
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 2.58
- RSI (14)
- 53
- Avg Volume
- 6.19M
No earnings-call transcripts are available for STEK yet.
- Free Float
- 89.5%
- Shares Outstanding
- 2.17B
- Float Shares
- 1.94B
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 23, 25 | KAPLAN BENJAMIN NATHANIEL | sell | 1,000,000 |
| Jul 26, 24 | ARNOLD CHARLES STUART | buy | 25,000 |
| Apr 19, 24 | Mindshare Holdings, Inc. | sell | 25,000 |
| Aug 8, 23 | Green Darryl V | other | 1,254,818 |
| Jun 12, 23 | Green Darryl V | other | 2,408,818 |
| Jun 12, 23 | ARNOLD CHARLES STUART | other | 8,333,333 |
| Sep 2, 21 | KAPLAN BENJAMIN NATHANIEL | other | 0 |
| Sep 2, 21 | KAPLAN BENJAMIN NATHANIEL | other | 0 |
| Sep 2, 21 | KAPLAN BENJAMIN NATHANIEL | other | 0 |
| Sep 2, 21 | Meyer John William | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our STEK coverage
Recent articles, reports, and earnings notes.
No research on STEK yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate STEK report →Physician Research Points to a New Frontier for Stemtech Corporation: Nutritional Activation of the Body's Endogenous Regenerative System
accessnewswire.com · Oct 8
Physician Cites Stemtech as "Cornerstone" Behind His Focus on STEM Cell Medicine
accessnewswire.com · Sep 22
Stemtech Corporation Appoints Alejandro Carrillio President, Latin Markets
accessnewswire.com · Aug 20
Stemtech Corporation Declares July 2026 "Cellular Health Awareness Month"
accessnewswire.com · Jul 1
Stemtech Corporation Issues 2025 Year-In-Review Letter Highlighting Corporate Strength, Global Expansion and Accelerating Market Opportunities
accessnewswire.com · Jun 23
Stemtech Secures Inventory Funding
accessnewswire.com · Apr 7
Stemtech Revolution 2026: A Bold New Era In Global Wellness
accessnewswire.com · Mar 18
Stemtech Corporation Launches New Market Channel Biosciences Ecommerce
accessnewswire.com · Feb 26
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.